Last updated on December 2018

Open Label Study to Evaluate Safety Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).


Brief description of study

To describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab (AMG 145) when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.

Detailed Study Description

An open label, single arm study to evaluate the safety and tolerability of 80 weeks of SC evolocumab when added to standard of care in pediatric subjects 10 to 17 years of age with HeFH or HoFH.

Clinical Study Identifier: NCT02624869

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Cincinnati, OH United States
  Connect »

Amgen Call Center

Research Site
Camperdown, Australia
  Connect »

Amgen Call Center

Research Site
Feldkirch, Austria
  Connect »

Amgen Call Center

Research Site
Wien, Austria
  Connect »

Amgen Call Center

Research Site
Chicoutimi, QC Canada
  Connect »

Amgen Call Center

Research Site
Quebec, QC Canada
  Connect »

Amgen Call Center

Research Site
Svitavy, Czechia
  Connect »

Amgen Call Center

Research Site
Athens, Greece
  Connect »

Amgen Call Center

Research Site
Thessaloniki, Greece
  Connect »

Amgen Call Center

Research Site
Budapest, Hungary
  Connect »

Amgen Call Center

Research Site
Palermo, Italy
  Connect »

Amgen Call Center

Research Site
Pisa, Italy
  Connect »

Amgen Call Center

Research Site
Roma, Italy
  Connect »

Amgen Call Center

Research Site
Torino, Italy
  Connect »

Amgen Call Center

Research Site
Amsterdam, Netherlands
  Connect »

Amgen Call Center

Research Site
Oslo, Norway
  Connect »

Amgen Call Center

Research Site
Parktown, South Africa
  Connect »

Amgen Call Center

Research Site
Geneva 14, Switzerland
  Connect »

Amgen Call Center

Research Site
Reinach, Switzerland
  Connect »

Amgen Call Center

Research Site
Izmir, Turkey
  Connect »

Amgen Call Center

Research Site
Ankara, Turkey
  Connect »

Amgen Call Center

Research Site
Birmingham, United Kingdom
  Connect »

Amgen Call Center

Research Site
Gent, Belgium
  Connect »

Amgen Call Center

Research Site
Barranquilla, Colombia
  Connect »

Amgen Call Center

Research Site
Parow, South Africa
  Connect »

Amgen Call Center

Research Site
Cordoba, Spain
  Connect »

Amgen Call Center

Research Site
Fortaleza, Brazil
  Connect »

Amgen Call Center

Research Site
Lugo, Spain
  Connect »

Amgen Call Center

Research Site
Salzburg, Austria
  Connect »

Amgen Call Center

Research Site
La Louvière, Belgium
  Connect »

Amgen Call Center

Research Site
São Paulo, Brazil
  Connect »

Amgen Call Center

Research Site
A Coruña, Spain
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.